GlassScriptPhysician profile
Jaspreet Hehar
NPI 1336595362
$2,566.58
in general payments reported to CMS, 2019-2025
29 companies · $849 in 2025
The $849 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $282 · 2020: $96.81 · 2021: $32.27 · 2022: $122 · 2023: $650 · 2024: $535 · 2025: $849.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,001 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,000.85 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $525.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $337.70 | 2022-2025 | Evenity, Tepezza, Prolia |
| Abbott Laboratories | $323.82 | 2023-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $264.36 | 2023-2025 | Dexcom G6 Transmitter |
| Radius Health, INC. | $136.77 | 2019-2024 | Tymlos |
| Lilly USA, LLC | $108.75 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Medtronic, INC. | $88.42 | 2024-2025 | Minimed 780g |
| Insulet Corporation | $85.31 | 2023-2025 | Omnipod |
| Abbvie INC. | $72.57 | 2023-2025 | |
| Mannkind Corporation | $65.14 | 2023-2025 | Afrezza |
| Tandem Diabetes Care, INC. | $55.95 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ascensia Diabetes Care US INC. | $51.35 | 2024 | |
| Sanofi-Aventis U.S. LLC | $46.41 | 2024-2025 | |
| Madrigal Pharmaceuticals | $43.75 | 2025 | Rezdiffra |
| Alexion Pharmaceuticals, INC. | $42.31 | 2023-2025 | Strensiq |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $36.11 | 2024 | Unithroid |
| Ascendis Pharma Endocrinology INC | $35.76 | 2025 | Yorvipath |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.48 | 2025 | Jardiance |
| Neurocrine Biosciences, INC. | $30.01 | 2024 | Crenessity |
| Antares Pharma, INC. | $25.88 | 2025 | Xyosted |
| Verity Pharmaceuticals INC. | $24.99 | 2025 | Trelstar |
| Rhythm Pharmaceuticals, INC. | $24.83 | 2025 | Imcivree |
| Amryt Pharma Holdings LTD | $18.18 | 2023 | Mycapssa |
| Alvogen INC | $18.01 | 2023 | Teriparatide |
| Beta Bionics, INC. | $17.89 | 2024 | Ilet Bionic Pancreas |
| Ibsa Pharma INC. | $16.00 | 2025 | Flector, Tirosint, Licart |
| Horizon Therapeutics Plc | $13.48 | 2023 | Tepezza |
| Xeris Pharmaceuticals, INC. | $13.16 | 2024 | Gvoke Hypopen |
| Theracosbio, LLC | $12.35 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaspreet Hehar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.